KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Assets (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Assets data on record, last reported at $1.6 billion in Q4 2025.

  • For Q4 2025, Assets rose 31.69% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, up 31.69%, while the annual FY2025 figure was $1.6 billion, 31.69% up from the prior year.
  • Assets reached $1.6 billion in Q4 2025 per ACAD's latest filing, up from $1.3 billion in the prior quarter.
  • Across five years, Assets topped out at $1.6 billion in Q4 2025 and bottomed at $587.8 million in Q4 2022.
  • Average Assets over 5 years is $859.5 million, with a median of $736.7 million recorded in 2021.
  • Peak YoY movement for Assets: decreased 17.34% in 2022, then skyrocketed 58.59% in 2024.
  • A 5-year view of Assets shows it stood at $700.1 million in 2021, then fell by 16.04% to $587.8 million in 2022, then grew by 27.41% to $749.0 million in 2023, then surged by 58.59% to $1.2 billion in 2024, then skyrocketed by 31.69% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $1.6 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.2 billion in Q2 2025.